Paper - WANFANG MED ONLINE

You Position: Home > Paper

Therapeutic effects of intravitreal implantation of Dexamethasone and Ranibizumab in the treatment of retinal vein occlusion

( views:39, downloads:14 )

Author:: No author available

Journal Title:: International Eye Science

Issue:: 12

DOI:: 10.3980/j.issn.1672-5123.2022.12.19

Key Word:: 视网膜静脉阻塞;黄斑水肿;地塞米松;雷珠单抗;疗效

Abstract：目的:比较地塞米松玻璃体内植入与玻璃体注射雷珠单抗治疗视网膜静脉阻塞(RVO)的疗效.方法:回顾性研究.选取本院40例ROV患者,根据治疗方式不同分为2组,A组采用地塞米松玻璃体内植入进行治疗,B组采用玻璃体腔注射雷珠单抗,比较两组患者治疗前后眼压、黄斑中心凹厚度(CMT)、最佳矫正视力(BCVA)、浅层血管复合体(SVC)层、深层血管复合体(DVC)层、脉络膜层与脉络膜毛细血管层黄斑区血流密度(MVD)、黄斑中心凹无血管区(FAZ)面积,记录复发及不良反应情况.结果:两组患者治疗12mo BCVA、CMT均较治疗前得到明显改善(P<0.05),但两组间比较无显著差异(P>0.05);治疗后,两组间SVC层、脉络膜层、脉络膜毛细血管层MVD比较均无显著差异(P>0.05),A组DVC层MVD显著大于B组(P<0.05);两组患者治疗前后浅层与深层FAZ面积比较均无显著差异(P>0.05);两组患者治疗后结膜下出血、异物感发生率比较均无显著差异(P>0.05),A组高眼压发生率明显高于B组(P<0.05);两组患者黄斑水肿(ME)复发率比较无显著差异(P>0.05),但A组平均复发时间明显长于B组(P<0.05).结论:相较于玻璃体腔注射雷珠单抗,地塞米松玻璃体内植入可更好增加DVC层MVD,疗效维持时间更长,但应注意高眼压不良反应风险.

Reference

[1]黎晓新,王宁利,梁小玲,等.地塞米松玻璃体腔植入剂治疗中国患者视网膜静脉阻塞继发黄斑水肿的安全性和有效性：随机、假注射对照、多中心研究[J].2018,(3).
[2]郭超,周庆芸,李琦.地塞米松玻璃体植入剂治疗视网膜静脉阻塞性黄斑水肿的研究概况[J].2019,(15).
[3]Mert.Simsek,Mehmet.Citirik,Serdar.Ozates,etc.The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario[J].2018,66(6).
[4]I. V. Zlobin,S. I. Zhukova,A. G. Shchuko,etc.Complex assessment of retinal ischemic damage in patients with retinal vein occlusion[J].2019,135(2).
[5]邱煦,窦宏亮,陈凤华,等.玻璃体腔注射抗血管内皮生长因子药物对视网膜微循环的影响研究现状与进展[J].2020,(7).
[6]Hykin, Philip,Prevost, A. Toby,Vasconcelos, Joana C.,etc.Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion A Randomized Clinical Trial[J].2019,137(11).
[7]Schmidt-Erfurth, Ursula,Garcia-Arumi, Jose,Gerendas, Bianca S.,etc.Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA)[J].2019,242(3).
[8]lias Georgalas,Ioannis Tservakis,Eftychia Eleftheria Kiskira,etc.Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study[J].2019,38(4).
[9].Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials[J].2020,45(5).
[10]Balal S.,Than J..Dexamethasone Intravitreal Implant Therapy for Retinal Vein Occlusion Macular Oedema and Conversion to Ranibizumab in Clinical Practice[J].2018,239(1).
[11]Ozkaya, Abdullah,Tanir, Ipek,Tarakcioglu, Hatice Nur.Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes[J].2018,95(12).
[12]Emrullah,Beyazy?ld?z,Mehmet,??t?r?k,Mert,?im?ek,etc.Branch retinal vein occlusion%mean platelet volume%plateletcrit%platelet distribution width%platelet parameters%retina,[J].2019,49(1).
[13]Catharina Busch,Matus Rehak,Chintan Sarvariya,etc.Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant[J].2019,103(4).
[14]Yin, Xue,Li, Jianqin,Zhang, Bingyu,etc.Association of glaucoma with risk of retinal vein occlusion: A meta-analysis[J].2019,97(7).
[15]Sibylle Winterhalter,Annabelle Eckert,Gerrit-Alexander vom Brocke,etc.Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months[J].2018,256(2).
[16]Falavarjani, Khalil Ghasemi,Iafe, Nicholas A.,Hubschman, Jean-Pierre,etc.Optical Coherence Tomography Angiography Analysis of the Foveal Avascular Zone and Macular Vessel Density After Anti-VEGF Therapy in Eyes With Diabetic Macular Edema and Retinal Vein Occlusion[J].2017,58(1).
[17].Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion[J].2020,4(1).
[18]Qiuming,Hu,Haoyu,Li,Wenhua,Xu,etc.Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.[J].2019,67(11).
[19]Houben, Isabeau,De Zaeytijd, Julie,Deghislage, Catherine,etc.Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy[J].2018,34(10).
[20]Chatziralli, Irini,Theodossiadis, George,Kabanarou, Stamatina A.,etc.Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study[J].2017,255(10).
[21]Costanzo, Eliana,Parravano, Mariacristina,Gilardi, Marta,etc.Microvascular Retinal and Choroidal Changes in Retinal Vein Occlusion Analyzed by Two Different Optical Coherence Tomography Angiography Devices[J].2019,242(1).
[22]Meiaad Khayat,Michael Williams,Noemi Lois.Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion[J].2018,63(6).
[23]Chiara,Giuffrè,Maria Vittoria,Cicinelli,Alessandro,Marchese,etc.Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion.[J].2020,258(4).